RayzeBio, Inc. Common Stock (RYZB) Stock Analysis

RayzeBio, Inc. Common Stock (RYZB) Healthcare & Pipeline Overview

RayzeBio, Inc., a clinical-stage biotechnology firm, specializes in radiopharmaceutical therapeutics for cancer, highlighted by its lead candidate RYZ101 targeting GEP-NETs in Phase 3 trials. The company leverages proprietary peptides and small molecules for targeted delivery of radioisotopes, positioning it within the evolving landscape of precision oncology.

What Is the Investment Thesis for RYZB?

RayzeBio presents a notable research candidate within the radiopharmaceutical therapeutics sector. The company's lead candidate, RYZ101, is in Phase 3 trials for GEP-NETs, a market with significant unmet need. Positive trial results could drive substantial revenue growth. The company's pipeline, including RYZ801 for HCC, offers further upside potential. The company's market cap is $3.75B. Key risks include clinical trial failures, regulatory hurdles, and competition. The company's high beta of 3.79 indicates high volatility. The company's P/E ratio is -35.73, reflecting its current lack of profitability. Successful commercialization of RYZ101 and advancement of its pipeline are key value drivers.

Based on FMP financials and quantitative analysis

RYZB Key Highlights

RayzeBio's lead drug candidate, RYZ101, is in Phase 3 clinical trials for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

• The company is developing RYZ801, a novel proprietary peptide that targets GPC3 for the treatment of hepatocellular carcinoma (HCC).
• RayzeBio is also developing RYZ811, a paired diagnostic imaging agent.
• The company has a novel proprietary small molecule that targets CA9 for the treatment of ccRCC.
• RayzeBio was incorporated in 2020 and is based in San Diego, California.

Who Are RYZB's Competitors?

RYZB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RYZB's Key Strengths?

Lead drug candidate (RYZ101) in Phase 3 clinical trials.

• Proprietary targeting molecule and radioisotope delivery technology.
• Experienced management team with expertise in radiopharmaceutical therapeutics.
• Strong intellectual property portfolio.

What Are RYZB's Weaknesses?

Clinical-stage company with no currently approved products.

• Reliance on the success of its clinical trials.
• High cash burn rate.
• Limited commercial infrastructure.

What Could Drive RYZB Stock Higher?

RYZ101 Phase 3 clinical trial data readout for GEP-NETs (expected in late 2026).

• Initiation of Phase 1/2 clinical trial for RYZ801 in HCC (expected in early 2027).
• Enrollment of patients in ongoing clinical trials.
• Potential for strategic partnerships or collaborations.

What Are the Key Risks for RYZB?

Insider selling — insiders were net sellers of roughly $109.0M recently.

• Clinical trial failures for RYZ101 or other RPTs.
• Regulatory delays or rejection of RPTs.
• Competition from other radiopharmaceutical therapeutics companies.
• High cash burn rate and need for additional financing.
• Dependence on key personnel.

What Are the Growth Opportunities for RYZB?

• Expansion of RYZ101 into earlier lines of therapy for GEP-NETs: Currently in Phase 3 for later-line GEP-NETs, expanding RYZ101's use to earlier stages of the disease could significantly increase its market potential. The addressable market for first-line GEP-NET treatment is estimated to be $500 million annually. This expansion would require additional clinical trials but could be a substantial growth driver by 2029.
• Development and commercialization of RYZ801 for HCC: Hepatocellular carcinoma (HCC) represents a large unmet medical need, and RYZ801's targeted approach offers a potential advantage over existing therapies. The HCC market is projected to reach $4 billion by 2028. Successful clinical development and commercialization of RYZ801 could generate significant revenue for RayzeBio.
• Advancement of RYZ811 as a companion diagnostic: RYZ811, the paired diagnostic imaging agent, can be used to identify patients who are most likely to respond to RYZ801. This personalized medicine approach could improve treatment outcomes and increase the adoption of RYZ801. The market for companion diagnostics is growing rapidly, driven by the increasing focus on precision medicine. This is an ongoing opportunity.
• Strategic partnerships and collaborations: RayzeBio could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its RPTs. These partnerships could provide access to additional funding, expertise, and market reach. The timeline for such partnerships is uncertain but could occur at any point.
• Expansion into new cancer targets: RayzeBio's proprietary targeting molecule and radioisotope delivery technology can be applied to other cancer types beyond GEP-NETs and HCC. Identifying and developing RPTs for new cancer targets could significantly expand the company's addressable market. This is a long-term growth opportunity, with potential product launches in the 2030s.

What Are RYZB's Competitive Advantages?

• Proprietary targeting molecules (peptides and small molecules) that selectively deliver radioisotopes to cancer cells.
• Expertise in radiopharmaceutical therapeutics development and manufacturing.
• Strong intellectual property portfolio protecting its RPTs.
• Clinical trial data demonstrating the safety and efficacy of its RPTs.

What Does RYZB Do?

RayzeBio, Inc., incorporated in 2020 and based in San Diego, California, is a biopharmaceutical company focused on developing innovative radiopharmaceutical therapeutics (RPTs) for the treatment of cancer. The company's mission is to improve outcomes for patients with cancer by creating targeted therapies that deliver potent radioisotopes directly to tumor cells. RayzeBio's lead drug candidate, RYZ101, is currently in a Phase 3 clinical trial for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a type of cancer that originates in the hormone-producing cells of the pancreas or gastrointestinal tract. Beyond RYZ101, RayzeBio is developing a pipeline of RPTs targeting various cancer types. This includes RYZ801, a novel proprietary peptide targeting GPC3 for the delivery of Ac225 in the treatment of hepatocellular carcinoma (HCC), a common type of liver cancer. The company is also developing RYZ811, a paired diagnostic imaging agent, and a novel proprietary small molecule targeting CA9 for the treatment of ccRCC. RayzeBio's approach involves the use of targeting molecules, such as peptides and small molecules, to selectively deliver radioisotopes to cancer cells while minimizing exposure to healthy tissues. This targeted approach has the potential to improve the efficacy and safety of cancer treatment. With a team of 88 employees, RayzeBio is committed to advancing its pipeline of RPTs and bringing new treatment options to patients with cancer.

What Products and Services Does RYZB Offer?

• Develop radiopharmaceutical therapeutics (RPTs) for cancer treatment.
• Target cancer cells with proprietary peptides and small molecules.
• Deliver potent radioisotopes directly to tumor cells.
• Conduct clinical trials to evaluate the safety and efficacy of RPTs.
• Develop companion diagnostics to identify patients who are most likely to respond to RPTs.
• Seek regulatory approval for RPTs from health authorities.
• Commercialize RPTs to treat patients with cancer.

How Does RYZB Make Money?

• Develop and patent novel radiopharmaceutical therapeutics.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Commercialize approved therapies through direct sales or partnerships.

What Industry Does RYZB Operate In?

RayzeBio operates in the biotechnology industry, specifically within the radiopharmaceutical therapeutics (RPT) market. This market is experiencing growth due to advancements in targeted therapies and the increasing prevalence of cancer. The competitive landscape includes companies developing similar RPTs, as well as established pharmaceutical companies with oncology portfolios. RayzeBio aims to differentiate itself through its proprietary targeting molecules and radioisotope delivery technology. The global oncology market is projected to reach $350 billion by 2030, presenting a significant opportunity for companies like RayzeBio.

Who Are RYZB's Key Customers?

• Patients with cancer, specifically GEP-NETs and HCC.
• Oncologists and other healthcare professionals who treat cancer patients.
• Hospitals and cancer centers that administer RPTs.
• Payers, including insurance companies and government healthcare programs.

How RayzeBio, Inc. Common Stock Is Valued

RayzeBio, Inc. Common Stock carries a market capitalization of $3.75B, placing it in the mid-cap category.

Company Profile

RayzeBio, Inc. Common Stock operates in the Biotechnology industry within the Healthcare sector. The company is led by CEO Kenneth Song. RYZB has traded publicly since 2023.

Return on equity for RayzeBio, Inc. Common Stock stands at 82.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -21.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -1.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 28.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.8%, the inverse of the P/E and a quick read on earnings relative to price.

The most recent 12 insider filings for RayzeBio, Inc. Common Stock break down as 6 sales and 6 purchases. On net that is roughly 1.4M shares disposed (about $109.0M), a signal worth weighing alongside the fundamentals.

RYZB Financials

RYZB Latest News

No recent news available for RYZB.

What Investors Ask About RayzeBio, Inc. Common Stock (RYZB) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources